Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiepitope Peptide Vaccine + GM-CSF + KLH in Metastatic Melanoma
NCT00153569Phase 2Unknown
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2003
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tyrosinase + MAGE-3 + GnTV in melanoma, sponsored by Charité – Universitätsmedizin Berlin. Status: unknown.
02
Drugs
tyrosinase + MAGE-3 + GnTV
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00153569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00153569.